Quick answers
- What is Ertapenem sodium used for?
- The FDA-approved label (Invanz, Merck Sharp & Dohme LLC, February 4, 2026) says: “INVANZ is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections. Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. Community-acquired pneumonia. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Ertapenem sodium have a boxed warning?
- No. None of the 20 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Ertapenem sodium?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Ertapenem sodium been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Ertapenem sodium?
- 16 companies list prescription products of Ertapenem sodium in the FDA NDC Directory, including Eugia US LLC, Apotex Corp. and Hikma Pharmaceuticals USA Inc..
What Ertapenem sodium is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
INVANZ is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections. Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. Community-acquired pneumonia. …
— FDA label: Invanz, Merck Sharp & Dohme LLC, effective February 4, 2026. Read the full label on DailyMed →
The FDA has 20 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 20 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection, powder, lyophilized, for solution · Injection |
|---|---|
| Route | Intramuscular · Intravenous |
| Prescription products | 18 in the FDA NDC Directory |
| Brand names | Invanz |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| ertapenem sodium 1 g injection | Generic | $24.89 per unit |
| ertapenem sodium 1 g injection, powder, lyophilized, for solution | Generic | $24.89–$47.21 per unit 10 packages, lowest to highest |
| ertapenem sodium 1 g/20 mL injection | Generic | $24.89 per unit |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Eugia US LLC2 products
- Apotex Corp.2 products
- Hikma Pharmaceuticals USA Inc.2 products
- Endo USA, Inc.2 products
- Sagent Pharmaceuticals2 products
- Hospira, Inc.1 product
- NorthStar RxLLC1 product
- Savior Lifetec Corporation1 product
- Gland Pharma Limited1 product
- Dr.Reddys Laboratories Inc1 product
- Merck Sharp & Dohme LLC1 product
- WG Critical Care, LLC1 product
- Fosun Pharma USA Inc.1 product
- Qilu Antibiotics Pharmaceutical Co., Ltd.1 product
- Fresenius Kabi USA, LLC1 product
- BluePoint Laboratories1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021337 INVANZ | Msd Sub Merck | November 21, 2001 | 31, latest March 17, 2022 2022: Labeling · 2020: Labeling · 2019: Labeling |
Generic approvals (5)
- ANDA208790Acs Dobfar Spa · April 16, 2018
- ANDA209133Eugia Pharma · June 25, 2018
- ANDA207647Savior Lifetec Corp · March 19, 2019
- ANDA212040Gland · March 26, 2021
- ANDA218067Qilu Antibiotics · October 31, 2024
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1734683, 1734686 |
|---|---|
| SPL set ID of the quoted label | 33f3b99b-fa82-42e0-26bf-f49891ae3d22 |
| FDA labels (SPL) | 20 |
| FDA applications | NDA021337, 5 ANDA |
| Active ingredients (FDA) | ERTAPENEM |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Invanz, Merck Sharp & Dohme LLC, effective February 4, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →